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AML is characterized by excessive proliferation and
infiltration of neoplastic cells of hematopoietic origin.
AML occurs at a median age of 67 and will lead to an
estimated 10,460 deaths in the United States in 2014.
Therapy for AML has changed little in the last 30 years,
and consists of an induction regimen of cytotoxic che-
motherapy, followed by consolidation therapy and
hematopoietic stem cell transplantation for appropriate
patients. Unfortunately, outcomes from standard therapy
are disappointing and most patients succumb to pro-
gressive disease or complications of therapy.
AML is thought to arise in and be perpetuated by a
small population of leukemic stem cells, characterized as
CD34+, CD38-, that also express high levels of CD123, the
interleukin-3 receptor alpha chain. The corresponding
fraction of cells from normal bone marrow demonstrates
low or undetectable expression of CD123. Based on these
observations, targeting CD123 could be a promising strat-
egy in the preferential ablation of AML cells. The Dual-
Affinity Re-Targeting (DART®) technology, is a proprie-
tary antibody-based platform that has been designed to
engage multiple targets with a single molecule. MGD006
is a novel CD123 × CD3 DART protein that targets
CD123-positive cells for recognition and elimination by
co-engagement of CD3-expressing T lymphocytes. In non-
clinical studies, the ability of MGD006 to mediate redir-
ected T cell killing of leukemic cells was demonstrated
across multiple CD123-expressing target tumor cell lines,
with efficacy generally correlating with the level of CD123
cell surface expression. Preclinical toxicology studies in
cynomolgus monkeys demonstrated that MGD006 could
be administered as a continuous intravenous infusion at
doses achieving circulating MGD006 levels that exceeded
those that demonstrated anti-leukemic activity in vitro,
with acceptable safety.
We have designed a Phase I dose-escalation study to
investigate the safety, pharmacokinetics and preliminary
activity of MDG006 in patients with relapsed/refractory
AML. The study employs single patient cohorts starting
at a dose equivalent to the minimum anticipated biolo-
gical effect level (MABEL) of MGD006 to establish the
starting dose for a subsequent standard 3+3 dose escala-
tion to define the maximum tolerated dose of MGD006.
This currently enrolling study represents the first clini-
cal use of DART molecules in patients with cancer.
ClinicalTrials.gov identifier NCT02152956.
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